Pharmaceutical company Eli Lilly and Company (NYSE:LLY) announced on Friday that it is planning to invest over USD3.5bn in a new manufacturing facility in the Lehigh Valley, Pennsylvania.

Serving as Lilly's newest injectable medicine and device manufacturing facility, the site will produce next-generation weight-loss therapies, including retatrutide, a first-in-class investigational GIP, GLP-1 and glucagon triple hormone receptor agonist. This is the fourth new US manufacturing site Lilly has announced since February 2025, as part of its commitment to bolster domestic medicine production.

Lilly says that it will bring 850 high-value jobs to the area, including engineers, scientists, operations personnel and lab technicians. Construction, expected to begin in 2026, is anticipated to generate 2,000 construction jobs. The site will be operational in 2031.